R. Scott Turner, PhD, MD, FANA, FAAN
Professor, Department of Neurology
Director, Memory Disorders Program
Georgetown University
Washington, DC
James E. Galvin, MD, MPH
Alexandria and Bernard Schoninger Endowed Chair in Memory Disorders
Professor of Neurology, Psychiatry & Behavioral Sciences
Chief, Division of Cognitive Neurology
Director, Comprehensive Center for Brain Health
Director and Principal Investigator, Lewy Body Dementia Research Center of Excellence
Principal Investigator, Native Alzheimer’s Disease Resource Center for Minority Aging Research (NAD-RCMAR)
University of Miami Miller School of Medicine
Boca Raton, Florida

Program Description

The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an emerging approach that have the potential to further alter practice. Clinicians must incorporate CSF, PET, and eventually plasma biomarkers into practice to identify patients who are eligible for antiamyloid therapies and must tailor their procedures to incorporate these infusion therapies for patients with mild cognitive impairment due to AD or dementia due to mild AD. In this activity, Drs. James Galvin and Scott Turner answer commonly asked questions about the use of AD biomarkers in practice and implications of the results of biomarker testing.

Target Audience

This activity is designed to educate neurology clinicians, primary care clinicians, and geriatricians (MDs, PAs, NPs).

Educational Objectives

  1. Describe currently available biomarker modalities for the diagnosis of AD
  2. Incorporate biomarker results into more traditional diagnostic methods
  3. Utilize biomarkers to identify candidates for antiamyloid targeted therapies

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

James E. Galvin, MD Consulting fees: Biogen Inc., Bristol Myers Squibb, Cognivue, Eisai Inc, Eli Lilly and Company, F. Hoffmann-La Roche Inc. GE HealthCare, Genentech, Inc.; Ownership Interest: Cognivue

R. Scott Turner, MD Consulting fees: Re:Cognition Health; Contracted Research: Research support to Georgetown University from Alector, Inc., Biogen Inc., Cognition Therapeutics, Inc., Eisai Inc., Eli Lilly and Company, F. Hoffmann-La Roche Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., Vaccinex Inc., Vivoryon Therapeutics N.V.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.

Begin Activity
available resources
linked resources
Suggested Reading
Top 10

Top 10 Questions on Biomarkers in Early Alzheimer’s Disease

Improving Diagnosis and Use of Targeted Therapies